College of Human and Health Sciences, Charles Darwin University, Darwin, NT, Australia.
Alan Walker Cancer Care Centre, Northern Territory Radiation Oncology, Darwin, NT, Australia.
Dis Markers. 2019 Nov 18;2019:8632018. doi: 10.1155/2019/8632018. eCollection 2019.
Circulating microRNAs (miRNAs) are potential molecular biomarkers for cancer detection; however, little is known about their prognostic role in head and neck cancer. This current study is aimed at evaluating the role of novel miRNAs in the survival of head and neck cancer patients.
We performed a systematic literature search using online databases for articles published between December 2006 and February 2019. A meta-analysis was conducted to assess the correlation between miRNA expressions and overall survival (OS) among the selected head and neck cancer studies. After multilevel screening by reviewers, meta-analysis was performed using hazard ratios (HR) and associated 95% confidence interval (CI) of survival to calculate a pooled effect size.
A total of 1577 patients across 13 studies were included in the literature review, with 18 miRNAs upregulated and 4 miRNAs downregulated predicting a poor overall survival. The forest plot generated using cumulated survival data resulted in a pooled HR value of 2.943 (95% CI: 2.394-3.618) indicating a strong association of dysregulated miRNA expression with a poor outcome. Only 2 miRNAs-low levels of miR-9 and high levels of miR-483-5p-were observed in two studies, both showing a significant association with overall cancer survival.
To our knowledge, this is the first comprehensive systematic review and meta-analysis that examines the prognostic role of circulating miRNAs from blood in head and neck cancer patients. The combined effect estimates a HR across multiple studies and also supports the previous individual findings that an alteration in miRNA expression is highly associated with poor prognosis. This has the potential to use serum and/or plasma miRNAs as biomarkers and become novel tools for predicting the prognosis of head and neck cancer patients in the near future.
循环 microRNAs(miRNAs)是癌症检测的潜在分子生物标志物,但它们在头颈部癌症中的预后作用知之甚少。本研究旨在评估新型 miRNAs 在头颈部癌症患者生存中的作用。
我们使用在线数据库进行了系统的文献检索,检索了 2006 年 12 月至 2019 年 2 月期间发表的文章。进行荟萃分析以评估选定的头颈部癌症研究中 miRNA 表达与总生存率(OS)之间的相关性。经过评审员的多层次筛选,使用生存风险比(HR)和相关的 95%置信区间(CI)进行荟萃分析,以计算合并效应量。
共有 13 项研究中的 1577 例患者纳入文献复习,其中 18 个 miRNA 上调和 4 个 miRNA 下调预测总体生存率差。使用累积生存数据生成的森林图得出的合并 HR 值为 2.943(95%CI:2.394-3.618),表明 miRNA 表达失调与不良预后有很强的关联。只有两个 miRNA(低水平的 miR-9 和高水平的 miR-483-5p)在两项研究中观察到,这两项研究均显示与总体癌症生存率有显著相关性。
据我们所知,这是首次全面的系统评价和荟萃分析,研究了来自血液的循环 miRNAs对头颈部癌症患者的预后作用。综合效应估计了多项研究的 HR,也支持了之前的个别研究结果,即 miRNA 表达的改变与预后不良高度相关。这有可能使用血清和/或血浆 miRNAs 作为生物标志物,并在不久的将来成为预测头颈部癌症患者预后的新工具。